(Q34734247)

4 August 2017

1 reference

title

Recent progress in the pharmacotherapy of cancer pain (English)

1 reference

4 August 2017

0 references

Mercadante S

1

1 reference

4 August 2017

publication date

1 October 2001

1 reference

Expert Review of Anticancer Therapy

4 August 2017

published in

1 reference

4 August 2017

volume

1

1 reference

4 August 2017

issue

3

1 reference

4 August 2017

page(s)

487-494

1 reference

Predictive factors and opioid responsiveness in cancer pain

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.1.3.487

Factors influencing the opioid response in advanced cancer patients with pain followed at home: the effects of age and gender

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.1.3.487

Opioid responsiveness-primary diagnosis relationship in advanced cancer patients followed at home

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.1.3.487

Breakthrough pain in cancer patients: pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.1.3.487

Opioid rotation for cancer pain: rationale and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.1.3.487

The role of morphine glucuronides in cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.1.3.487

Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.1.3.487

21 January 2018

Methadone in cancer pain

1 reference

https://api.crossref.org/works/10.1586%2F14737140.1.3.487

Patient-controlled analgesia with oral methadone in cancer pain: preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.1.3.487

Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.1.3.487

Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.1.3.487

Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.1.3.487

Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.1.3.487

The use of anti-inflammatory drugs in cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.1.3.487

Malignant bone pain: pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.1.3.487

Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.1.3.487

Drug interactions in human neuropathic pain pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.1.3.487

21 January 2018

Identifiers

DOI

10.1586/14737140.1.3.487

1 reference

4 August 2017

1 reference